Rare Variants Associated With Interval Breast Cancers

Though common breast cancer variants indicate increased breast cancer risk, certain rare variants are associated with an increased risk for interval breast cancers and death, according to a study published in the Nov. 1 issue of Cancer Research.
Jingmei Li, Ph.D., from the Genome Institute of Singapore, and colleagues assessed whether the genetic risk stratification of breast cancer by rare and common variants in established loci can discriminate tumors with different biology, patient survival, and mode of detection among 5,099 patients with breast cancer diagnosed in Sweden between 2001 and 2008. The genetic risk load was evaluated through protein-truncating variant (PTV) carriership in 31 breast cancer predisposition genes or polygenic risk score (PRS) using 162 single-nucleotide polymorphisms.
The researchers found that PTV carriers (597 patients) were younger and were associated with more aggressive tumor phenotypes (estrogen receptor-negative, large size, high grade, high proliferation, luminal B, and basal-like subtype) and worse outcome (hazard ratio [HR], 1.65) versus noncarriers. PTV carriership remained associated with high grade and worse survival (HR, 1.76) even after 92 BRCA1/2 carriers were excluded. Higher PRS was associated with less aggressive tumor characteristics (estrogen receptor-positive, progesterone receptor-positive, small size, low grade, low proliferation, and luminal A subtype) in BRCA1/2 noncarriers. In women with low mammographic density, non-BRCA1/2 PTV carriers more often had interval than screen-detected disease (odds ratio, 1.89), but higher PRS was associated with a lower risk for interval-detected versus screen-detected cancer (odds ratio, 0.77).
"These findings offer the potential to improve screening practices for breast cancer by providing a deeper understanding of how risk variants affect disease progression and mode of detection," the authors write.
2026-10-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Nuohui Health tore off the 'B label', the beginning of China's cancer early screening industry to regain confidence
-
The female Jobs $9 billion scam failed, is the 'drop blood cancer test' a shocking scam, or a ray of hope?
-
L’ORÉAL SUED OVER HAIR STRAIGHTENING-PRODUCTS CANCER CLAIMS
-
Will the mRNA cancer vaccine come true?
-
Genentech Team Discovers New Cancer Immunotherapy Target - ESCRT
-
China Small Molecule Innovative Drugs Industry Trends to 2022
-
Prevent Diseases: Osimertinib Mechanism of Action
-
The European Union completely banned ranitidine or carcinogens
-
Study: Diet with fiber & yogurt may reduce lung cancer risk
-
A new generation of antibody-drug conjugates for cancer patients
Recommend Reading
-
New York’s Food Chemical Disclosure Bill Raises the Bar for GRAS Transparency
-
Jell-O Simply Shows Clean Label Reformulation Has Entered Legacy Brands
-
Dietary Supplement Listing Debate Puts Nutrition Ingredients Under a Brighter Spotlight
-
Syngenta’s VIRESTINA Targets Resistant Weeds as Herbicide Innovation Regains Urgency
-
Celanese to Close Acetate Tow Plant in Lanaken, Belgium by 2026
-
Business Society’s Market Outlook for Fuel Oil 180CST on August 25, 2026: Volatile
-
Cost Benefits Drive July Polyester Staple Fiber Prices to Fluctuate and Rise
-
Coke Market Stably Strong, Price Increase Implemented at Midnight on the 26th
-
Methylene Chloride Price Increase Slows, Expected to Stabilize with Slight Strength in the Short Term in China
-
MTBE Market Trend Shows Significant Decline in China
- Hot Searches
- 2cb for sale
- sodium hydroxide supplier
- hypochlorous acid wholesale supplier
- ammonium sulphate crystalline
- hong kong chemical reagent suppliers
- best igf-1 lr3 suppliers
- propylene price
- na 931 peptide for sale
- retatrutide buy online
- liquid neon
- dipotassium phosphate distributor
- mecoprop herbicide